Hypersensitivity Reactions to Histamine H2 ‐Receptor Antagonists ( H2RAs ): An EAACI Position Paper

Histamine H2-receptor antagonists (H2RAs) are widely used drugs which can induce immediate and delayed hypersensitivity reactions (HSRs) including anaphylaxis, urticaria, contact dermatitis, and severe cutaneous adverse reactions. The available evidence is limited by the fact that most data come from case reports and by the absence of large-scale studies. Furthermore, the reported cases are mostly linked to ranitidine, which has been withdrawn from the global market. Consequently, the pathogenesis of these reactions is unclear, resulting in significant clinical challenges. Limited data suggest the usefulness of skin tests (STs) in patients with suspected HSRs to H2RA, but optimal STs concentrations have yet to be established. The same applies to drug provocation tests (DPTs) protocols, which are not standardized. Therefore, the authors recommend taking a step-by-step diagnostic approach. Clinicians are advised to establish non-irritative STs concentrations by testing healthy control subjects. In patients with negative skin test results, supervised DPTs are recommended to confirm tolerance or identify safe alternatives. As cross-reactivity among H2RAs is inconsistent, alternative H2RAs should only be selected following a complete allergological work-up. Addressing these gaps is essential for the safe management of patients, particularly in the light of the recent global re-licensing of reformulated H2RAs.

Authors

Institutions

Publication Details

Journal
Allergy
Published
2026-11-20
DOI
https://doi.org/10.1111/all.70567
Primary Topic
Drug-Induced Adverse Reactions
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Hypersensitivity Reactions to Histamine H2 ‐Receptor Antagonists ( H2RAs ): An EAACI Position Paper

José Julio Laguna, Knut Brockow, Alla Nakonechna, Carla Lombardo et al.
Allergy
Drug-Induced Adverse Reactions
article

Hypersensitivity Reactions to Histamine H2 ‐Receptor Antagonists ( H2RAs ): An EAACI Position Paper

José Julio Laguna, Knut Brockow, Alla Nakonechna, Carla Lombardo, Seçil Kepil Özdemir, Annick M. Barbaud, Giorgia Marta, Sevim Bavbek, Patrizia Bonadonna, Marina Atanasković‐Marković, Mauro Pagani, Marı́a José Torres
article en

Abstract

Histamine H2-receptor antagonists (H2RAs) are widely used drugs which can induce immediate and delayed hypersensitivity reactions (HSRs) including anaphylaxis, urticaria, contact dermatitis, and severe cutaneous adverse reactions. The available evidence is limited by the fact that most data come from case reports and by the absence of large-scale studies. Furthermore, the reported cases are mostly linked to ranitidine, which has been withdrawn from the global market. Consequently, the pathogenesis of these reactions is unclear, resulting in significant clinical challenges. Limited data suggest the usefulness of skin tests (STs) in patients with suspected HSRs to H2RA, but optimal STs concentrations have yet to be established. The same applies to drug provocation tests (DPTs) protocols, which are not standardized. Therefore, the authors recommend taking a step-by-step diagnostic approach. Clinicians are advised to establish non-irritative STs concentrations by testing healthy control subjects. In patients with negative skin test results, supervised DPTs are recommended to confirm tolerance or identify safe alternatives. As cross-reactivity among H2RAs is inconsistent, alternative H2RAs should only be selected following a complete allergological work-up. Addressing these gaps is essential for the safe management of patients, particularly in the light of the recent global re-licensing of reformulated H2RAs.

Allergy
Ankara University (TR), Imperial College Healthcare NHS Trust (GB), Inserm (FR), Instituto de Salud Carlos III (ES), Sorbonne Université (FR), Ospedale Santa Chiara (IT), Assistance Publique – Hôpitaux de Paris (FR), Hospital Regional Universitario de Málaga (ES), Hospital Central de la Cruz Roja San José y Santa Adela (ES), Sağlık Bilimleri Üniversitesi (TR), HSU Dr. Suat Seren Chest Diseases and Chest Surgery Training and Research Hospital (TR), Institut Pierre Louis d‘Épidémiologie et de Santé Publique (FR), University Children's Hospital, Belgrade (RS), Universidad Alfonso X el Sabio (ES), Andalusian Centre for Nanomedicine and Biotechnology (ES), Instituto de Investigación Biomédica de Málaga (ES), Azienda Ospedaliera Carlo Poma (IT), Hôpital Tenon (FR), Azienda ULSS 8 Berica (IT), Technical University of Munich (DE), Universidad de Málaga (ES)
European Academy of Allergy and Clinical Immunology
Good health and well-being
Drug-Induced Adverse Reactions
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon